{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.4","upperLimit":"18.8","value":"14.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"}],"units":"Participants"}],"description":"OS was defined as the time from the date of the first dose of amatuximab to the date of death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received amatuximab 5 mg/kg, IV infusion on Days 1 and 8 with pemetrexed 500 mg/m\\^2, IV infusion on Day 1 and cisplatin 75 mg/ m\\^2, IV infusion on Day 1 of each 21-day cycle for approximately 6 cycles during combination therapy. Participants who completed 6 cycles of combination therapy or who discontinued chemotherapy because of intolerable toxicity continued receiving single agent amatuximab 5 mg/kg, IV infusion on Day 1 and 8 of each 21-day cycle until disease progression or death for all subsequent cycles (up to 52 Cycles \\[Cycle length is 21 days\\]).","id":"OG000","title":"All Participants"}],"paramType":"MEDIAN","populationDescription":"Safety population consisted of all participants who received at least 1 dose of amatuximab.","reportingStatus":"POSTED","timeFrame":"From the date of first dose to the date of death, up to approximately 5 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}